SoftOx Solutions AS (SOFTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SoftOx Solutions AS (SOFTX) has a cash flow conversion efficiency ratio of -0.355x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-8.16 Million ≈ $-858.46K USD) by net assets (Nkr22.95 Million ≈ $2.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SOFTX company net worth for the company's overall valuation and market capitalisation.
SoftOx Solutions AS - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how SoftOx Solutions AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SoftOx Solutions AS stock quote for real-time trading data and today's change.
SoftOx Solutions AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SoftOx Solutions AS ranked by their cash flow conversion efficiency. Review SOFTX free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kristal Kola ve Mesrubat Sanayi Ticaret AS
IS:KRSTL
|
0.003x |
|
Haverty Furniture Companies Inc
NYSE:HVT-A
|
0.104x |
|
DocGo Inc
NASDAQ:DCGO
|
-0.042x |
|
True North Copper Ltd
AU:TNC
|
-0.033x |
|
Imas Makina Sanayi AS
IS:IMASM
|
0.046x |
|
Tactical Resources Corp. Common Shares
NASDAQ:TREO
|
0.048x |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
0.085x |
|
Samwha Elec
KO:011230
|
-0.075x |
Annual Cash Flow Conversion Efficiency for SoftOx Solutions AS (2017–2025)
The table below shows the annual cash flow conversion efficiency of SoftOx Solutions AS from 2017 to 2025. Also see SoftOx Solutions AS balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr22.95 Million ≈ $2.42 Million |
Nkr-18.87 Million ≈ $-1.99 Million |
-0.822x | -340.27% |
| 2024-12-31 | Nkr95.18 Million ≈ $10.02 Million |
Nkr32.56 Million ≈ $3.43 Million |
0.342x | +6.98% |
| 2023-12-31 | Nkr2.37 Million ≈ $249.01K |
Nkr756.68K ≈ $79.62K |
0.320x | +105.96% |
| 2022-12-31 | Nkr16.01 Million ≈ $1.68 Million |
Nkr-85.94 Million ≈ $-9.04 Million |
-5.369x | -557.42% |
| 2021-12-31 | Nkr88.85 Million ≈ $9.35 Million |
Nkr-72.56 Million ≈ $-7.64 Million |
-0.817x | -3.07% |
| 2020-12-31 | Nkr76.22 Million ≈ $8.02 Million |
Nkr-60.39 Million ≈ $-6.35 Million |
-0.792x | -548.68% |
| 2019-12-31 | Nkr86.47 Million ≈ $9.10 Million |
Nkr-10.56 Million ≈ $-1.11 Million |
-0.122x | +88.22% |
| 2018-12-31 | Nkr14.41 Million ≈ $1.52 Million |
Nkr-14.94 Million ≈ $-1.57 Million |
-1.037x | -81.43% |
| 2017-12-31 | Nkr26.85 Million ≈ $2.83 Million |
Nkr-15.34 Million ≈ $-1.61 Million |
-0.571x | -- |
About SoftOx Solutions AS
SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx So… Read more